翰宇药业：目前公司多肽原料药总产能可达5吨以上

Core Viewpoint - The company has indicated that its total production capacity for peptide raw materials exceeds 5 tons, with specific annual production plans being dynamically formulated based on market and collaboration demands [1] Group 1 - The company, Hanyu Pharmaceutical, has confirmed its current production capacity for peptide raw materials is over 5 tons [1] - The annual production schedule for specific products will be determined by market conditions and collaboration needs [1]